retatrutide approval 2025 The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight-loss results, retatrutide approval 2025 Retatrutide vs.

This accelerated timeline is directly attributable to the glucagon receptor activation, which adds the thermogenic and lipolytic effects that single and dual agonists lack

Microdosing GLP-1 medications can help patients stretch their FDA-approved GLP-1 medication

Semaglutide and Tirzepatide are innovative medications used for managing type 2 diabetes and weight loss, but they have key differences in their composition and mechanisms of action

Albumin-binding tag derived exendin-4 analogue for treating hyperglycemia and diabetic complications

Many people treated with these medications will have gastrointestinal side effects like nausea and constipation, and these often abate over time